LENSAR Inc
NASDAQ:LNSR

Watchlist Manager
LENSAR Inc Logo
LENSAR Inc
NASDAQ:LNSR
Watchlist
Price: 7.38 USD -0.94% Market Closed
Market Cap: 85.7m USD
Have any thoughts about
LENSAR Inc?
Write Note

LENSAR Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LENSAR Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
LENSAR Inc
NASDAQ:LNSR
Selling, General & Administrative
-$26.1m
CAGR 3-Years
-3%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Selling, General & Administrative
-$4.9B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-9%
Boston Scientific Corp
NYSE:BSX
Selling, General & Administrative
-$5.8B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-7%
Stryker Corp
NYSE:SYK
Selling, General & Administrative
-$7.2B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Abbott Laboratories
NYSE:ABT
Selling, General & Administrative
-$11.5B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-6%
Intuitive Surgical Inc
NASDAQ:ISRG
Selling, General & Administrative
-$2.1B
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
-12%
No Stocks Found

LENSAR Inc
Glance View

Market Cap
85.2m USD
Industry
Health Care

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

LNSR Intrinsic Value
8.59 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is LENSAR Inc's Selling, General & Administrative?
Selling, General & Administrative
-26.1m USD

Based on the financial report for Dec 31, 2023, LENSAR Inc's Selling, General & Administrative amounts to -26.1m USD.

What is LENSAR Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-10%

Over the last year, the Selling, General & Administrative growth was 4%. The average annual Selling, General & Administrative growth rates for LENSAR Inc have been -3% over the past three years , -10% over the past five years .

Back to Top